• Andrew M Naidech, Monisha A Kumar, and Participants in the International Multidisciplinary Consensus Conference on Multimodality Monitoring.
• Departments of Neurology, Neurosurgery, Northwestern University, Chicago, IL, USA, a-naidech@northwestern.edu.
• Neurocrit Care. 2014 Dec 1; 21 Suppl 2: S168-76.

AbstractAnemia and bleeding are paramount concerns in neurocritical care and often relate to the severity of intracranial hemorrhage. Anemia is generally associated with worse outcomes, and efforts to minimize anemia through reduced volume of blood sampled are encouraged. Point-of-care-testing reliably detects the use of non-steroidal anti-inflammatory drugs that may worsen bleeding and reduce platelet activity, particularly in patients with intracerebral hemorrhage. How best to monitor the effect of platelet transfusion or platelet-activating therapy is not well studied. For patients known to take novel oral anticoagulants, drug-specific coagulation tests before neurosurgical intervention are prudent.

20 keywords...

hide…